Stoyanovsky DA, Jiang J, Murphy MP et al (2014) Design and synthesis of a mitochondria-targeted mimic of glutathione peroxidase, mitoebselen-2, as a radiation mitigator
Minimal Discomfort and Downtime: While some patients may experience mild discomfort or bruising at the injection sites, the treatment is generally well-tolerated with minimal downtime
The overall response rate (ORR) for CM patients to ipilimumab, nivolumab, pembrolizumab and atezolizumab is 12%, 40%, 33% and 30% respectively (167169), while the combined treatment of ipilimumab with nivolumab significantly improves the ORR to 61% with median progression-free survival (PFS) of 11.5 months (170, 171)
The lesion is monitored at recall appointments
Agefine sells over the counter worldwide as cosmetic skincare
Acad Emerg Med 2001, 8: 999-1001